Search
Search Results
-
Biosimilars in Ovarian Cancer
Ovarian cancer is a deadly malignancy and remains to be a formidable challenge in respect to oncology, that is characterized by its insidious onset,...
-
Germline mutations of 4567 patients with hereditary breast-ovarian cancer spectrum in Thailand
Multi-gene panel testing has led to the detection of pathogenic/likely pathogenic (P/LP) variants in many cancer susceptibility genes in patients...
-
Breast Cancer
Breast cancers are a major cause of mortality in females, on a par with lung and colon cancers. One topic in this chapter are the causes of breast...
-
Extended genetic analysis and tumor characteristics in over 4600 women with suspected hereditary breast and ovarian cancer
BackgroundGenetic screening for pathogenic variants (PVs) in cancer predisposition genes can affect treatment strategies, risk prediction and...
-
EMQN best practice guidelines for genetic testing in hereditary breast and ovarian cancer
Hereditary Breast and Ovarian Cancer (HBOC) is a genetic condition associated with increased risk of cancers. The past decade has brought about...
-
Molecular Characterization of Single Circulating Tumor Cells in Breast and Ovarian Cancer
Epithelial ovarian cancer (EOC)Epithelial ovarian cancer (EOC) still has the highest mortality rate of all gynecological malignancies, diagnosed...
-
Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer
Use of gonadotropin-releasing hormone (GnRH) agonists has been widely adopted to provide reversible ovarian function suppression for pre-menopausal...
-
Immunotherapy in Breast Cancer
Breast cancer affects 12% of women worldwide. Although advances in systemic, surgical, and radiation therapy approaches will cure a large proportion...
-
Breast Cancer
Breast cancer is currently the most diagnosed cancer in the female population, with a prevalence of 1 in 8 women.
-
Inhibiting PRMT5 induces DNA damage and increases anti-proliferative activity of Niraparib, a PARP inhibitor, in models of breast and ovarian cancer
BackgroundInhibitors of
P oly (A DP-R ibose)P olymerases (PARP) provide clinical benefit to patients with breast and ovarian cancers, by compromising...
-
Psychosocial barriers and facilitators for cascade genetic testing in hereditary breast and ovarian cancer: a sco** review
Despite increased awareness and availability of genetic testing for hereditary breast and ovarian cancer (HBOC) syndrome for over 20 years, there is...
-
Decision-analytic evaluation of the comparative effectiveness and cost-effectiveness of strategies to prevent breast and ovarian cancer in German women with BRCA-1/2 mutations
BackgroundWomen with inherited mutations in the BRCA1 or BRCA2 genes have increased lifetime risks for develo** breast and/or ovarian cancer and...
-
Resistance to Immunotherapy in Breast Cancer
Breast cancer is the most common and second most deadly disease in women worldwide, with breast cancer screening resulting in a steady decline in...
-
Menopausal hormone therapy use and risk of ovarian cancer by race: the ovarian cancer in women of African ancestry consortium
BackgroundMost studies examining post-menopausal menopausal hormone therapy (MHT) use and ovarian cancer risk have focused on White women and few...
-
Cascade testing in Italian Hereditary Breast Ovarian Cancer families: a missed opportunity for cancer prevention?
Healthy carriers of BRCA1/2 pathogenic variants (PVs) may benefit from risk-reducing measures of proven efficacy. The main approach to identify these...
-
Resistance to Endocrine Therapy in Breast Cancer
The foremost cause of female deaths is due to breast cancer. The most frequent type of breast cancer is hormone-dependent breast cancer, being either...
-
Diagnostic-Prognostic Biomarkers and Their Clinical Implication in Breast Cancer
Breast cancer (BC) is a complex disease that continues to affect global cancer fatalities with its high incidence rate. Hence, BC requires...
-
Inhibition of branched-chain alpha-keto acid dehydrogenase kinase augments the sensitivity of ovarian and breast cancer cells to paclitaxel
ContextMany cancer patients who initially respond to chemotherapy eventually develop chemoresistance, and to address this, we previously conducted a...
-
Epigenetics of Breast Cancer
Epigenetic modulations of gene expression, post-transcriptional silencing of messenger RNA (mRNA), and post-translational modifications of protein...
-
Genomic Landscape of Breast Cancer
Understanding the genomic landscape of breast cancer is a very active and rapidly evolving research area. Genome wide searches have been conducted by...